Systemic administration of dacomitinib efficiently impaired EGFR signaling in vivo and affected the growth and survival of tumors formed from EGFR-amplified GBM cells, independent of the presence of different mutant receptor isoforms [53]. The gene discussed is EGFR; the disease is glioblastoma.